BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8374538)

  • 1. Recurrence of acute leukemia in donor cells after bone marrow transplantation: documentation by in situ DNA hybridization.
    Mouratidou M; Sotiropoulos D; Deremitzaki K; Spathas DH; Hoffbrand AV; Prentice HG; Papanastasiou K; Tsakanikas S; Tsaftaridis P; Stamatelou M
    Bone Marrow Transplant; 1993 Jul; 12(1):77-80. PubMed ID: 8374538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation.
    Glasser L; Meloni-Ehrig A; Greaves W; Demel KC; Butera J
    Transfusion; 2009 Mar; 49(3):555-62. PubMed ID: 19040490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature.
    Reichard KK; Zhang QY; Sanchez L; Hozier J; Viswanatha D; Foucar K
    Am J Hematol; 2006 Mar; 81(3):178-85. PubMed ID: 16493618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
    Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
    Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation.
    Bielorai B; Deeg HJ; Weintraub M; Neumann Y; Rosner E; Amariglio N; Rechavi G; Toren A
    Bone Marrow Transplant; 2003 May; 31(10):931-4. PubMed ID: 12748672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ hybridization using a Y-specific probe--a sensitive method for distinguishing residual male recipient cells from female donor cells in bone marrow transplantation.
    Wessman M; Ruutu T; Volin L; Knuutila S
    Bone Marrow Transplant; 1989 May; 4(3):283-6. PubMed ID: 2659113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is leukemic transformation of donor cells possible?].
    Vinogradova OA; Savchenko VG; Domracheva EV; Parovichnikova EN; Diachenko LV; Alimova GA; Mendeleeva LP; Liubimova LS; Sokolov AN; Zhelnova EI; Pokrovskaia OS
    Ter Arkh; 2004; 76(7):28-34. PubMed ID: 15379124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune evasion strategies of pediatric precursor-B acute lymphoblastic leukemia after allogeneic bone marrow transplantation-a case study.
    Barbaric D; Wynne K; Aslanian S; Bond M; Reid GS
    Leuk Res; 2005 Jun; 29(6):711-4. PubMed ID: 15863213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
    Huang H; Lin M; Meng H
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Ataergin S; Arpaci F; Cetin T; Guran S; Yakicier C; Beyzadeoglu M; Ozet A
    Am J Hematol; 2006 May; 81(5):370-3. PubMed ID: 16628734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow].
    Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP
    Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation.
    Au WY; Lie AK; Lee CK; Liang R; Kwong YL
    Bone Marrow Transplant; 1999 Jun; 23(11):1201-3. PubMed ID: 10382962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis.
    Wessman M; Popp S; Ruutu T; Volin L; Cremer T; Knuutila S
    Bone Marrow Transplant; 1993 Apr; 11(4):279-84. PubMed ID: 8485475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
    Saito Y; Uzuka Y; Sakai N; Suzuki S; Toyota T
    Bone Marrow Transplant; 2000 Jun; 25(11):1209-11. PubMed ID: 10849535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.